SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 68.61-2.5%Jul 11 9:30 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (3142)9/9/2017 3:04:42 PM
From: tuck  Read Replies (1) of 3202
 
IDO/PD1 combo battle part 2: Here is the data for Epacadostat/Keytruda in melanoma:

Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma

Again, to preserve formatting, just the permalink. Without knowing baseline characteristics of the ECHO patients, not sure how things stand. Here's a presentation with baseline characteristics for Indoximod/Keytruda combo. Apparently, the dose here was 1200mg/kg, whereas they are taking half that dose into P3, which is interesting, because the SAE profile looks OK, and no worse than Epacadostat . . .

Interim Analysis of the Phase 2 Clinical Trial of the IDO Pathway Inhibitor Indoximod in Combination With Pembrolizumab for Patients With Advanced Melanoma

Both open label. Again, with out ECHO baseline data, hard to compare well, but based on what we have, I give the edge to Indoximod. Better looking safety, better CR rate, similar ORR, slightly better mPFS. No wonder NLNK had more than a one day tear.

ECHO data more mature? CR rate is down from previous look.

Always interested in other opinions.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext